Investment
Features
FeesSafety
Academy
More
Pluang+

Compare LYFT Inc (LYFT) vs Mesoblast Limited (MESO) Price & Performance

Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

LYFT Inc vs Mesoblast Limited — how do they compare? LYFT Inc trades at $17.5 (market cap $6.64B), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: LYFT Inc is far larger — about 3× Mesoblast Limited's market cap. Which is the better fit depends on your goals.

LYFTMESO
Market Cap
$6.64B$2.21B
Sector
IndustrialsTechnology
52-Week High
$24.57$20.96
52-Week Low
$12.65$12.88
Enterprise Value
$6.11B$2.21B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

LYFT Inc

No Aura AI signal available yet.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About LYFT Inc

Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.

Read more on LYFT

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO